Nature communications · 2026
Allogeneic hematopoietic cell transplantation in mature T- or NK-lymphomas: a phase II clinical trial.
СтатьяКлиническое исследование II фазыНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rechache Kamil A, Nunes Natalia S, Sponaugle Jennifer, Xue Elisabetta, Chai Amy, Combs Rebecca, Campos Jessenia, Feng Xingmin, Flomerfelt Francis A, Upadhyaya Kalpana, Telford William, Dawson Brian, Hughes Thomas E, Shah Syed Muhammad Salman, Peluso Alicia, McKeown Christi, Stokes Anita, Napier Scott, Sabina Ruby, Wilder Jennifer, Cole Kristen, Baruffaldi Judy, Cuellar-Rodriguez Jennifer, Gea-Banacloche Juan, Czech Mary M, Hyder Mustafa A, Kanakry Christopher G, Dimitrova Dimana, Kanakry Jennifer A
Аннотация
Allogeneic hematopoietic cell transplantation (HCT) is a potential cure for patients with peripheral T-/NK-cell lymphomas (PTCL), but its application is understudied. This prospective trial evaluates a unique reduced-intensity (RIC) transplantation platform in 31 patients with PTCL (NCT03922724). One-year progression-free survival, the primary endpoint, is 53% (95% CI 29-72%) on the RIC arm and 60% (95% CI 25-83%) on the modified-RIC arm. The 3-year overall survival is 61% (95% CI 42-76%), with relapse estimated at 18% (95% CI 6-34%) at 3 years. Transplant-related mortality was 24% (95% CI 10-41%) at 1-year, low at 11% (95% CI 2-29%) for patients ≤60 years but 56% (95% CI 17-82%) for patients >60 years, p = 0.01. There was no grade III-IV acute graft-versus-host disease, while chronic graft-versus-host disease was estimated at 23% (95 CI 10-38%) at 2 years. This study demonstrates a benefit regardless of pre-transplantation disease status, challenging the requirement of remission for HCT.